17 August, 2018
The report of the Rhinology Future Debates 2017 is now available online.Novel developments in #Rhinology are presented to a panel of experts and patients, and the strengths, weaknesses and potential positioning in the care pathways are debatedhttps://onlinelibrary.wiley.com/doi/abs/10.1111/coa.13184/
The Rhinology Future Debate took place in Brussels in December 2017 as a discussion forum in the respiratory field. The panel concluded that patient-friendly treatment approaches are important.
The KOS treatment was concluded to be a patient-friendly technique as a non-surgical option of idiopathic rhinitis and chronic nose congestion.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.